Tag: electronic kidney fibrosis treatment market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Kidney Fibrosis Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The kidney fibrosis treatment market size has demonstrated robust growth in recent years. It is anticipated to increase from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The growth observed in the past can be attributed to several factors including the rising prevalence of chronic kidney disease, the limited effectiveness of conventional therapies, the increased use of ACE inhibitors and ARBs, the growing healthcare burden of renal failure, and the expansion of nephrology care services.

The kidney fibrosis treatment market size is projected for substantial expansion in the coming years. It is anticipated to reach $8.84 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period can be primarily ascribed to advancements in specific antifibrotic agents, an expanding elderly demographic afflicted with chronic kidney disease (CKD), the increasing integration of precision medicine within nephrology, heightened investment in renal research, and enhanced diagnosis of early-stage kidney disease. Key developments expected in this period encompass a heightened emphasis on developing antifibrotic drugs, a growing prevalence of combination therapies for CKD, increased research into stem cell and regenerative treatments, the expansion of tools for early diagnosis and monitoring, and an escalation in clinical trials focused on renal fibrosis pathways.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=23699152&type=smp&name=Kidney%20Fibrosis%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Kidney Fibrosis Treatment Market Growth Drivers: What’s Behind The Acceleration?

The expanding prevalence of chronic kidney diseases is poised to drive the growth of the kidney fibrosis treatment market in the future. Chronic Kidney Disease (CKD) is characterized by a gradual deterioration of kidney function over time, often caused by underlying conditions such as diabetes or hypertension, leading to the accumulation of waste substances in the body. The escalation in CKD prevalence is largely attributable to the increasing rates of diabetes, which impairs kidney blood vessels and their filtering capabilities. Kidney fibrosis treatment offers assistance to CKD patients by targeting the scarring of renal tissue, mitigating inflammation, and decelerating the progression of kidney damage, ultimately preserving renal function. As an illustration, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, projected that the global total of newly diagnosed chronic kidney diseases would climb to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney diseases is a key factor propelling the kidney fibrosis treatment market.

Kidney Fibrosis Treatment Market Segment Analysis: What Are The Core Market Categories?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Kidney Fibrosis Treatment Market Trends: What’s Defining The Industry’s Next Phase?

Major companies in the kidney fibrosis treatment market are concentrating on targeted ileal-release immunomodulatory therapies, such as NEFECON. This oral delayed-release budesonide capsule is designed to deliver the drug specifically to the distal ileum, aiming to modulate gut-associated B-cells and reduce pathogenic IgA production, thereby slowing the progression of kidney fibrosis in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a biopharmaceutical company based in China, introduced NEFECON. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the core cause of IgA nephropathy, and has proven its ability to significantly reduce kidney function decline.

Kidney Fibrosis Treatment Market Top Companies Driving Competitive Growth

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

View The Full Kidney Fibrosis Treatment Market Report:

https://thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Kidney Fibrosis Treatment Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Kidney Fibrosis Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The kidney fibrosis treatment market size has demonstrated robust growth in recent years. It is anticipated to increase from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The growth observed in the past can be attributed to several factors including the rising prevalence of chronic kidney disease, the limited effectiveness of conventional therapies, the increased use of ACE inhibitors and ARBs, the growing healthcare burden of renal failure, and the expansion of nephrology care services.

The kidney fibrosis treatment market size is projected for substantial expansion in the coming years. It is anticipated to reach $8.84 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period can be primarily ascribed to advancements in specific antifibrotic agents, an expanding elderly demographic afflicted with chronic kidney disease (CKD), the increasing integration of precision medicine within nephrology, heightened investment in renal research, and enhanced diagnosis of early-stage kidney disease. Key developments expected in this period encompass a heightened emphasis on developing antifibrotic drugs, a growing prevalence of combination therapies for CKD, increased research into stem cell and regenerative treatments, the expansion of tools for early diagnosis and monitoring, and an escalation in clinical trials focused on renal fibrosis pathways.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=23699152&type=smp&name=Kidney%20Fibrosis%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Kidney Fibrosis Treatment Market Growth Drivers: What’s Behind The Acceleration?

The expanding prevalence of chronic kidney diseases is poised to drive the growth of the kidney fibrosis treatment market in the future. Chronic Kidney Disease (CKD) is characterized by a gradual deterioration of kidney function over time, often caused by underlying conditions such as diabetes or hypertension, leading to the accumulation of waste substances in the body. The escalation in CKD prevalence is largely attributable to the increasing rates of diabetes, which impairs kidney blood vessels and their filtering capabilities. Kidney fibrosis treatment offers assistance to CKD patients by targeting the scarring of renal tissue, mitigating inflammation, and decelerating the progression of kidney damage, ultimately preserving renal function. As an illustration, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, projected that the global total of newly diagnosed chronic kidney diseases would climb to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney diseases is a key factor propelling the kidney fibrosis treatment market.

Kidney Fibrosis Treatment Market Segment Analysis: What Are The Core Market Categories?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Kidney Fibrosis Treatment Market Trends: What’s Defining The Industry’s Next Phase?

Major companies in the kidney fibrosis treatment market are concentrating on targeted ileal-release immunomodulatory therapies, such as NEFECON. This oral delayed-release budesonide capsule is designed to deliver the drug specifically to the distal ileum, aiming to modulate gut-associated B-cells and reduce pathogenic IgA production, thereby slowing the progression of kidney fibrosis in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a biopharmaceutical company based in China, introduced NEFECON. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the core cause of IgA nephropathy, and has proven its ability to significantly reduce kidney function decline.

Kidney Fibrosis Treatment Market Top Companies Driving Competitive Growth

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

View The Full Kidney Fibrosis Treatment Market Report:

https://thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Kidney Fibrosis Treatment Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Kidney Fibrosis Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The kidney fibrosis treatment market size has demonstrated robust growth in recent years. It is anticipated to increase from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The growth observed in the past can be attributed to several factors including the rising prevalence of chronic kidney disease, the limited effectiveness of conventional therapies, the increased use of ACE inhibitors and ARBs, the growing healthcare burden of renal failure, and the expansion of nephrology care services.

The kidney fibrosis treatment market size is projected for substantial expansion in the coming years. It is anticipated to reach $8.84 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period can be primarily ascribed to advancements in specific antifibrotic agents, an expanding elderly demographic afflicted with chronic kidney disease (CKD), the increasing integration of precision medicine within nephrology, heightened investment in renal research, and enhanced diagnosis of early-stage kidney disease. Key developments expected in this period encompass a heightened emphasis on developing antifibrotic drugs, a growing prevalence of combination therapies for CKD, increased research into stem cell and regenerative treatments, the expansion of tools for early diagnosis and monitoring, and an escalation in clinical trials focused on renal fibrosis pathways.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=23699152&type=smp&name=Kidney%20Fibrosis%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Kidney Fibrosis Treatment Market Growth Drivers: What’s Behind The Acceleration?

The expanding prevalence of chronic kidney diseases is poised to drive the growth of the kidney fibrosis treatment market in the future. Chronic Kidney Disease (CKD) is characterized by a gradual deterioration of kidney function over time, often caused by underlying conditions such as diabetes or hypertension, leading to the accumulation of waste substances in the body. The escalation in CKD prevalence is largely attributable to the increasing rates of diabetes, which impairs kidney blood vessels and their filtering capabilities. Kidney fibrosis treatment offers assistance to CKD patients by targeting the scarring of renal tissue, mitigating inflammation, and decelerating the progression of kidney damage, ultimately preserving renal function. As an illustration, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, projected that the global total of newly diagnosed chronic kidney diseases would climb to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney diseases is a key factor propelling the kidney fibrosis treatment market.

Kidney Fibrosis Treatment Market Segment Analysis: What Are The Core Market Categories?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Kidney Fibrosis Treatment Market Trends: What’s Defining The Industry’s Next Phase?

Major companies in the kidney fibrosis treatment market are concentrating on targeted ileal-release immunomodulatory therapies, such as NEFECON. This oral delayed-release budesonide capsule is designed to deliver the drug specifically to the distal ileum, aiming to modulate gut-associated B-cells and reduce pathogenic IgA production, thereby slowing the progression of kidney fibrosis in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a biopharmaceutical company based in China, introduced NEFECON. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the core cause of IgA nephropathy, and has proven its ability to significantly reduce kidney function decline.

Kidney Fibrosis Treatment Market Top Companies Driving Competitive Growth

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

View The Full Kidney Fibrosis Treatment Market Report:

https://thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Kidney Fibrosis Treatment Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Kidney Fibrosis Treatment Market Value Expansion And Long-Term Growth Outlook

The kidney fibrosis treatment market has experienced robust expansion in recent years, projected to rise from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historic growth is driven by factors such as the increasing incidence of chronic kidney disease, the insufficient efficacy of standard treatments, a greater reliance on ACE inhibitors and ARBs, the escalating healthcare strain associated with renal failure, and the broader availability of nephrology care services.

The kidney fibrosis treatment market is projected to experience robust expansion over the coming years, reaching an estimated value of $8.84 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period is fueled by progress in developing targeted antifibrotic agents, a rising elderly population affected by chronic kidney disease (CKD), the increasing application of precision medicine within nephrology, heightened investment in renal research, and enhanced capabilities for early-stage kidney disease detection. Key trends shaping the forecast period include a heightened emphasis on creating antifibrotic drugs, a growing adoption of combination therapies for CKD, expanding investigations into stem cell and regenerative treatments, the broadening availability of early diagnostic and monitoring technologies, and a surge in clinical trials focused on renal fibrosis pathways.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Kidney Fibrosis Treatment Market Development Factors: Which Trends Are Supporting Demand?

The growth of the kidney fibrosis treatment market is anticipated to be driven forward by the rising incidence of chronic kidney diseases. Chronic kidney disease (CKD) entails a gradual decline in kidney functionality over an extended period, frequently stemming from ailments such as diabetes or hypertension, which lead to the buildup of bodily waste. This escalating prevalence of CKD is predominantly fueled by increasing diabetes rates, a condition that harms kidney blood vessels and compromises their filtration capabilities. Kidney fibrosis treatment benefits CKD sufferers by addressing the scarring of renal tissue, diminishing inflammation, and decelerating kidney damage progression, thereby helping to maintain renal function. As reported in July 2025 by Hamadan University of Medical Sciences, an Iranian academic institution, the worldwide number of new chronic kidney disease diagnoses is expected to reach 25.06 million by 2030. Consequently, the increasing occurrence of chronic kidney diseases is propelling expansion within the kidney fibrosis treatment market.

Kidney Fibrosis Treatment Market Segments: Where Are The Largest Growth Opportunities?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Kidney Fibrosis Treatment Market Transformation Trends: Which Innovations Are Driving Change?

Leading players in the kidney fibrosis treatment space are placing emphasis on targeted ileal-release immunomodulatory approaches, including NEFECON, which is an oral delayed-release budesonide capsule designed to deliver the medication precisely to the distal ileum. This mechanism modulates gut-associated B-cells, curbing pathogenic IgA production, and thereby decelerating kidney fibrosis progression in individuals with IgA nephropathy. As an example, Everest Medicines, a biopharmaceutical company based in China, introduced NEFECON in June 2024. This therapy employs an enteric-coated, delayed-release formulation to limit systemic steroid exposure, acts on mucosal B-cells in the gut to tackle the underlying cause of IgA nephropathy, and has been shown to substantially reduce the decline in kidney function.

Kidney Fibrosis Treatment Market Major Participants And Competitive Dynamics

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Access The Complete Kidney Fibrosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Kidney Fibrosis Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Kidney Fibrosis Treatment Market Change Between 2026 And 2030?

The kidney fibrosis treatment market has demonstrated significant growth in recent years. It is anticipated to increase from $6.06 billion in 2025 to $6.54 billion in 2026, with a compound annual growth rate (CAGR) of 8.0%. The expansion observed in previous periods is attributable to factors such as the increasing incidence of chronic kidney disease, the restricted efficacy of traditional therapies, the greater utilization of ACE inhibitors and ARBs, the rising healthcare burden due to renal failure, and the extended provision of nephrology care services.

The kidney fibrosis treatment market size is expected to demonstrate robust growth in the coming years, with projections indicating an expansion to **$8.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%**. This growth over the forecast period is primarily driven by advancements in targeted antifibrotic agents, an expanding aging population suffering from chronic kidney disease (CKD), the increasing adoption of precision medicine within nephrology, escalating investments in renal research, and improvements in the early diagnosis of kidney disease. Significant trends anticipated during this period include an intensified focus on the development of antifibrotic drugs, a greater utilization of combination therapies for CKD, a surge in research concerning stem cell and regenerative therapies, the expansion of early diagnostic and monitoring tools, and an increase in clinical trials targeting renal fibrosis pathways.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Strategic Drivers Are Supporting The Kidney Fibrosis Treatment Market Development?

The expanding occurrence of chronic kidney diseases is set to drive the growth of the kidney fibrosis treatment market. Chronic kidney disease (CKD) is characterized by a progressive decline in kidney function over time, often triggered by conditions such as diabetes or hypertension, which results in the buildup of waste products in the body. The increasing incidence of CKD is largely attributed to the rising prevalence of diabetes, a condition that damages kidney blood vessels and impedes their filtering capacity. Kidney fibrosis treatment offers assistance to CKD patients by addressing the scarring of kidney tissue, reducing inflammation, and decelerating the progression of kidney damage, thereby preserving kidney function. As an illustration, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, projected that the global count of newly diagnosed chronic kidney diseases will escalate to 25.06 million by 2030. Hence, the rising prevalence of chronic kidney diseases is fueling the growth of the kidney fibrosis treatment market.

What Segment Types Are Included In The Kidney Fibrosis Treatment Market Analysis?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Trends Are Influencing The Expansion Of The Kidney Fibrosis Treatment Market?

Major companies engaged in the kidney fibrosis treatment market are prioritizing specific ileal-release immunomodulatory therapies, such as NEFECON, which is an oral delayed-release budesonide capsule engineered to deliver the medication directly to the distal ileum. This mechanism modulates gut-associated B-cells and diminishes pathogenic IgA production, thereby decelerating the progression of kidney fibrosis in patients with IgA nephropathy. For instance, in June 2024, Everest Medicines, a China-based biopharmaceutical company, launched NEFECON. This treatment incorporates an enteric-coated, delayed-release formulation to lessen systemic steroid exposure, targets mucosal B-cells in the gut to address the core cause of IgA nephropathy, and has demonstrated a significant capability to reduce the decline in kidney function.

Which Companies Are Engaged In The Kidney Fibrosis Treatment Market Environment?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Access The Complete Kidney Fibrosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Region Holds The Largest Share In The Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Kidney Fibrosis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Kidney Fibrosis Treatment Market During The Forecast Period?

The market for kidney fibrosis treatment has seen significant expansion in recent years. It is projected to grow from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical development can be attributed to the rising prevalence of chronic kidney disease, the limited effectiveness of conventional therapies, increased usage of ACE inhibitors and ARBs, the escalating healthcare burden from renal failure, and the expansion of nephrology care services.

The kidney fibrosis treatment market is projected to experience substantial growth in the upcoming years, with its size anticipated to reach $8.84 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This expansion during the forecast period is primarily attributed to significant advancements in targeted antifibrotic agents, the increasing aging population affected by ckd, the growing adoption of precision medicine in nephrology, escalating investment in renal research, and enhanced diagnostic capabilities for early-stage kidney disease. Key trends expected in this period encompass a heightened focus on antifibrotic drug development, a rising utilization of combination therapies for ckd, increasing research efforts in stem cell and regenerative therapies, the broader deployment of early diagnostic and monitoring tools, and an increase in clinical trials targeting renal fibrosis pathways.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Key Drivers Are Fueling The Growth Of The Kidney Fibrosis Treatment Market?

The anticipated expansion of the kidney fibrosis treatment market is linked to the rising incidence of chronic kidney diseases. Chronic Kidney Disease (CKD) involves a progressive decline in renal function, commonly caused by conditions like diabetes or hypertension, leading to the buildup of metabolic waste in the system. A primary factor contributing to the growing occurrence of CKD is the escalating prevalence of diabetes, which harms the kidney’s blood vessels and compromises their filtration capabilities. For individuals with CKD, kidney fibrosis treatment offers benefits by addressing renal tissue scarring, mitigating inflammation, and decelerating the advance of kidney deterioration, thereby sustaining kidney function. As an illustration, data from Hamadan University of Medical Sciences, an Iran-based university, indicates that by July 2025, the global count of new chronic kidney disease diagnoses is projected to ascend to 25.06 million by 2030. Consequently, the expanding occurrence of chronic kidney diseases is stimulating the growth within the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Categorized Across Its Segment Groups?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Trends Are Impacting The Progress Of The Kidney Fibrosis Treatment Market?

Leading companies in the kidney fibrosis treatment sector are concentrating on specialized ileal-release immunomodulatory treatments. An example is NEFECON, an oral budesonide capsule with delayed release that specifically targets the distal ileum to regulate gut-associated B-cells and decrease the production of pathogenic IgA, thereby decelerating kidney fibrosis progression in individuals with IgA nephropathy. As an illustration, Everest Medicines, a biopharmaceutical firm based in China, introduced NEFECON in June 2024. This treatment utilizes an enteric-coated, delayed-release design, which helps in minimizing the body’s exposure to systemic steroids. Its mechanism involves targeting mucosal B-cells within the gut, thereby tackling the fundamental cause of IgA nephropathy, and has proven effective in substantially slowing the deterioration of kidney function.

Which Firms Are Influencing Competition In The Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Get The Full Kidney Fibrosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Where Is The Kidney Fibrosis Treatment Market Most Concentrated Geographically?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Kidney Fibrosis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Kidney Fibrosis Treatment Market Over The 2026–2030 Period?

The kidney fibrosis treatment market size has experienced strong expansion in recent years. It is projected to increase from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The market’s growth during the historic period was primarily driven by factors such as the rising prevalence of chronic kidney disease, the limited effectiveness of traditional therapies, the increased adoption of ACE inhibitors and ARBs, the growing healthcare burden associated with renal failure, and the expansion of nephrology care services.

The market for kidney fibrosis treatments is projected to experience substantial growth over the coming years, anticipated to reach $8.84 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.8%. Key factors driving this expansion during the forecast period include progress in targeted antifibrotic therapies, a rising elderly demographic affected by CKD, the wider integration of precision medicine within nephrology, increased funding for renal research, and enhanced early detection of kidney disease. Significant trends expected during this period involve a heightened emphasis on developing antifibrotic drugs, a greater reliance on combination treatments for CKD, increased exploration into stem cell and regenerative treatments, the proliferation of tools for early diagnosis and monitoring, and an uptick in clinical trials aimed at renal fibrosis pathways.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Underlying Factors Are Accelerating The Growth Of The Kidney Fibrosis Treatment Market?

The future expansion of the kidney fibrosis treatment market is anticipated to be fueled by the growing occurrence of chronic kidney diseases. Chronic Kidney Disease (CKD) involves a progressive decline in kidney function over time, frequently caused by conditions like diabetes or high blood pressure, leading to the buildup of metabolic waste in the body. This surge in CKD prevalence is primarily attributed to the escalating rates of diabetes, a condition that harms renal blood vessels and compromises their filtration capacity. Kidney fibrosis treatment provides benefits to CKD patients by addressing the scarring of kidney tissue, alleviating inflammation, and decelerating the advance of kidney damage, thereby sustaining kidney function. For example, data from Hamadan University of Medical Sciences, an Iran-based university, projects that by 2030, the worldwide incidence of newly diagnosed chronic kidney diseases will reach 25.06 million, as reported in July 2025. Consequently, the rising occurrence of chronic kidney diseases is a key factor propelling the expansion of the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Segmented Across Key Categories?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Upcoming Trends Are Expected To Influence The Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are increasingly focusing on specialized ileal-release immunomodulatory therapies. NEFECON exemplifies this trend, functioning as an oral delayed-release budesonide capsule that delivers the drug precisely to the distal ileum. This mechanism helps to modulate gut-associated B-cells and reduce the production of pathogenic IgA, thereby slowing the progression of kidney fibrosis in patients with IgA nephropathy. For example, Everest Medicines, a China-based biopharmaceutical company, launched NEFECON in June 2024. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, directly targets mucosal B-cells in the gut to address the root cause of IgA nephropathy, and has shown significant potential in reducing kidney function decline.

Who Are The Dominant Players Shaping The Kidney Fibrosis Treatment Market Landscape?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Read the full kidney fibrosis treatment market report here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Region Is Projected To Dominate The Kidney Fibrosis Treatment Market During The Forecast Period?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kidney Fibrosis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the kidney fibrosis treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Kidney Fibrosis Treatment Market between 2026 and 2030?

The kidney fibrosis treatment market size has demonstrated significant growth in recent years. It is projected to increase from $6.06 billion in 2025 to $6.54 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This expansion during the historical period can be attributed to factors such as the rising occurrence of chronic kidney disease, the limited efficacy of traditional therapies, the increased adoption of ACE inhibitors and ARBs, the growing healthcare strain from renal failure, and the broadened provision of nephrology care services.

The kidney fibrosis treatment market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $8.84 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period is attributable to advancements in targeted antifibrotic agents, an increasing aging population affected by CKD, the growing adoption of precision medicine in nephrology, rising investment in renal research, and improved diagnosis of early-stage kidney disease. Major trends expected in the forecast period include a heightened focus on antifibrotic drug development, an expanding use of combination therapies for CKD, increased research in stem cell and regenerative therapies, the expansion of early diagnostic and monitoring tools, and a rising number of clinical trials targeting renal fibrosis pathways.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Kidney Fibrosis Treatment Market?

The rising incidence of chronic kidney diseases is anticipated to stimulate expansion in the kidney fibrosis treatment market. Chronic kidney disease (CKD) involves a progressive decline in kidney function over time, frequently caused by conditions like diabetes or hypertension, leading to the build-up of waste products within the body. The growing prevalence of CKD is primarily fueled by increasing diabetes rates, which harm renal blood vessels and hinder their filtering capacity. Kidney fibrosis treatment aids CKD patients by addressing the scarring of kidney tissue, alleviating inflammation, and decelerating the advance of kidney damage, thereby sustaining kidney function. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Consequently, the increasing prevalence of chronic kidney diseases is propelling growth within the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Organized Into Various Segments?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

What Long-Term Trends Are Expected To Shape The Future Of The Kidney Fibrosis Treatment Market?

Major companies active in the kidney fibrosis treatment market are directing their efforts towards targeted ileal-release immunomodulatory therapies, such as NEFECON. This oral delayed-release budesonide capsule specifically delivers the drug to the distal ileum to modulate gut-associated B-cells and decrease pathogenic IgA production, consequently slowing the progression of kidney fibrosis in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a biopharmaceutical company based in China, launched NEFECON. The therapy is formulated with an enteric-coated, delayed-release design to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the core issue of IgA nephropathy, and has shown significant ability to reduce the decline in kidney function.

Who Are The Top-Performing Companies In The Kidney Fibrosis Treatment Market In Recent Years?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Kidney Fibrosis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the kidney fibrosis treatment market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Kidney Fibrosis Treatment Market By The End Of 2029?

The kidney fibrosis treatment market size has experienced robust growth in recent years. It is projected to expand from $5.62 billion in 2024 to $6.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.8%. This historical expansion can be attributed to several factors, including heightened research and development investments in fibrosis-targeting therapies, increased government funding for kidney disease management initiatives, growing patient awareness of kidney transplantation and fibrosis treatment options, expanding healthcare infrastructure, and the rising prevalence of aging populations.

The kidney fibrosis treatment market size is anticipated to experience substantial growth over the next few years, reaching “$8.21 billion by 2029 at a compound annual growth rate (CAGR) of 7.9%.” This expansion during the forecast period is attributable to the increasing occurrence of chronic kidney diseases, a growing need for advanced therapies for managing renal fibrosis, heightened awareness of early-stage kidney fibrosis diagnosis, the expanding adoption of personalized medicine in kidney disease treatment, and the rising rates of diabetes and hypertension. Major trends expected in the forecast period include technological advancements in early detection and diagnostic tools, progress in gene therapy, the integration of technology in telemedicine and remote monitoring, breakthroughs in stem cell therapies, and innovations in drug delivery systems.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Business Drivers Are Underpinning The Growth Of The Kidney Fibrosis Treatment Market?

The rising occurrence of chronic kidney diseases is projected to drive expansion within the kidney fibrosis treatment market in the coming years. Chronic kidney disease (CKD) involves a progressive decline in kidney function over time, frequently stemming from conditions like diabetes or high blood pressure, leading to a buildup of waste materials in the body. The growing incidence of chronic kidney disease (CKD) is primarily fueled by increasing diabetes rates, which harm kidney blood vessels and compromise their capacity to filter. Treatment for kidney fibrosis aids chronic kidney disease (CKD) patients by addressing the scarring of renal tissue, lessening inflammation, and decelerating the advance of kidney damage, thereby preserving kidney function. For example, in May 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that an estimated 14% of U.S. adults, or approximately 35.5 million people, are thought to be suffering from chronic kidney diseases. Consequently, the rising prevalence of chronic kidney diseases is stimulating the expansion of the kidney fibrosis treatment market.

What Are The Principal Segment Types In The Kidney Fibrosis Treatment Market?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Companies Are Contributing Significantly To The Kidney Fibrosis Treatment Market Growth?

Major companies operating in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Region Offers The Most Opportunity For Kidney Fibrosis Treatment Market Expansion?

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2025, By The Business Research Company

Kidney Transplant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

Artificial Kidney Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-kidney-global-market-report

Rare Kidney Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model